DV
Dividend Vision

DSGN — Design Therapeutics Inc

Design Therapeutics Inc (DSGN)

Total return is -64.3% over the past 5.4 years, 174.8 points behind SPY at 110.5%. Its deepest 1-year drawdown was 35.6%.

DSGN is an equity fund focused on Design Therapeutics Inc, a single-stock holding in the biotechnology sector. The fund does not currently have a measurable distribution rate or expense ratio listed, indicating it may not offer regular dividend distributions. This fund appeals primarily to investors seeking direct exposure to a specific biotech company rather than those pursuing income-generating strategies.

DSGN key facts

Asset type
Stock
Asset class
Equity
Inception date
03/26/2021
Last close
$14.83
Market cap
$785,084,160
Average volume
259800.0
Beta
1.59
Payout ratio
0.0
Forward P/E
0.0
EPS
$-1.20